$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How much does a box of Cabozantinib cost in 2024?
2026-02-01 22:25:32
Check Details
Cabozantinib is developed and produced by which company?
2026-02-01 22:25:32
Check Details
What biological targets does Cabozantinib mainly act on?
2026-02-01 22:25:32
Check Details
What you must know about the contraindications for larotrectinib in the treatment of solid tumors
2026-02-01 22:25:32
Check Details
Analysis of the therapeutic effect of larotrectinib on NTRK gene fusion solid tumors
2026-02-01 22:25:32
Check Details
Application scope of larotrectinib in cancer treatment
2026-02-01 22:25:32
Check Details
17 indications for the targeted drug larotinib
2026-02-01 22:25:32
Check Details
How effective is lenvatinib in the treatment of liver cancer?
2026-02-01 22:25:32
Check Details
The role and limitations of lenvatinib in the treatment of thyroid cancer
2026-02-01 22:25:32
Check Details
Adverse reactions and coping strategies during lenvatinib treatment
2026-02-01 22:25:32
Check Details
Detailed interpretation of lenvatinib patient medication guide
2026-02-01 22:25:32
Check Details
Lenvatinib resistance phenomenon and countermeasures
2026-02-01 22:25:32
Check Details
1
2
...
771
772
773
774
775
776
777
...
10237
10238
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Vosoritide Side Effects and Pre-Injection Food/Fluid: Injection-Site Reactions, Transient Hypotension
2
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
3
Pretomanid Mechanism and BPaL Use in Drug-Resistant TB
4
Pacritinib Drug Contraindications and Precautions
5
Pomalidomide Side Effects, Risk Monitoring, and Precautions
6
Dasatinib for Ph+ Chronic Myeloid Leukemia: Dosage, Administration, and Long-Term Care
7
Obeticholic Acid 5 mg for PBC: Dosage, Risks, and Current Status
8
Acalabrutinib Monotherapy for CLL: What It Can and Cannot Do
9
Bepirovirsen for Chronic HBV Functional Cure: FDA Criteria and B-Well Data
10
After Ibrutinib Resistance: CLL/SLL and MCL Next Steps, Progression vs Intolerance
11
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
12
Quizartinib for FLT3-ITD AML: Induction-Consolidation-Maintenance and QT Monitoring